S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

ASX:TLX - TELIX Pharmaceutical Stock Price, Forecast & News

A$1.60
0.00 (0.00 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
A$1.58
Now: A$1.61
A$1.63
50-Day Range
A$1.42
MA: A$1.52
A$1.65
52-Week Range
A$0.65
Now: A$1.61
A$1.95
Volume131,045 shs
Average VolumeN/A
Market Capitalization$406.51 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. Its products include TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma; TLX250, which is in Phase II for the diagnosis and treatment of renal cancer; TLX250-CDx, which is in Phase III for the imaging of clear cell renal cell cancer; TLX591, which is in pre-Phase III for the treatment of metastatic castrate-resistant prostate cancer; and TLX591-CDx, which is in Phase III for the imaging of prostate cancer. The company has collaboration agreements with Radboud University, University of Nantes/ARRONAX, University of Melbourne Osaka University, Winship Cancer Institute of Emory University, Merck Healthcare KGaA, and Memorial Sloan Kettering, as well as the Institute for Radiation Sciences, Osaka University and the Department of Nuclear Medicine, and Tracer Kinetics at Osaka University Graduate School of Medicine. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.01 million
Cash FlowA$0.04 per share
Book ValueA$0.20 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$406.51 million
Next Earnings DateN/A
OptionableNot Optionable

Receive TLX News and Ratings via Email

Sign-up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter.


TELIX Pharmaceutical (ASX:TLX) Frequently Asked Questions

What is TELIX Pharmaceutical's stock symbol?

TELIX Pharmaceutical trades on the ASX under the ticker symbol "TLX."

Has TELIX Pharmaceutical been receiving favorable news coverage?

News stories about TLX stock have trended somewhat negative on Thursday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. TELIX Pharmaceutical earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for TELIX Pharmaceutical.

Who are some of TELIX Pharmaceutical's key competitors?

What other stocks do shareholders of TELIX Pharmaceutical own?

Who are TELIX Pharmaceutical's key executives?

TELIX Pharmaceutical's management team includes the folowing people:
  • Dr. Christian P. Behrenbruch B.E., M.B.A., BEng(Hons), MBA, DPhil(Oxon), J.D., Co-Founder, MD, CEO & Director (Age 44)
  • Mr. Douglas Cubbin FCPA, GAICD, Chief Financial Officer
  • Dr. Jyoti Arora BappSc(Hons), Ph.D., Director of Operations
  • Dr. Andreas Kluge M.D., Ph.D., Chief Medical Officer & Exec. Director
  • Mr. Gabriel Liberatore, Group Chief Operating Officer

What is TELIX Pharmaceutical's stock price today?

One share of TLX stock can currently be purchased for approximately A$1.61.

How big of a company is TELIX Pharmaceutical?

TELIX Pharmaceutical has a market capitalization of $406.51 million and generates $2.01 million in revenue each year. View Additional Information About TELIX Pharmaceutical.

What is TELIX Pharmaceutical's official website?

The official website for TELIX Pharmaceutical is http://www.telixpharma.com/.


MarketBeat Community Rating for TELIX Pharmaceutical (ASX TLX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  10 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  19
MarketBeat's community ratings are surveys of what our community members think about TELIX Pharmaceutical and other stocks. Vote "Outperform" if you believe TLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel